A Glasgow-based company which is developing a diagnostic tool to detect brain tumours is one of the organisations taking part in roundtable discussions today – 5 February – to review the brain tumour diagnosis pathway in Scotland.
GPs, NHS representatives, researchers, representatives from the Chief Scientist’s Office, the Scottish Steering Committee and The Brain Tumour Charity – representing the patient voice – are also taking part in the meeting at The Royal College of Physicians in Edinburgh.
More than 1,000 people in Scotland are diagnosed with a brain or central nervous system tumour each year1 so there is an urgent need to prioritise better care. In addition, The Charity’s Improving Brain Tumour Care surveys show one in three people visit their GP more than five times before they are diagnosed.
Now Dxcover Limited is working alongside researchers at the University of Edinburgh to develop a blood test and AI algorithms that could enable earlier diagnosis in primary care settings by analysing blood samples to look for signs of a brain tumour. Early research suggests that this technology could offer a promising diagnostic tool, although more testing is required.
Cameron Miller, Director of Policy and Strategy at The Brain Tumour Charity said: “This roundtable is a stepping stone to ensure that the right conversations are taking place while these diagnostic tools are being developed.
“When they are ready for patients, we want to ensure that they can access them as quickly as possible. It is also key to ensuring policymakers truly understand the barriers to brain tumour diagnosis and the need to improve current diagnostic pathways.”
Brain tumours can be hard to diagnose due to their non-specific symptoms, including headaches, vomiting and visual disturbances. An early diagnostic test to help identify which people with these symptoms are most likely to have a brain tumour would help prioritise demand on imaging facilities such as MRI and CT scans.
Dxcover is currently running a performance evaluation study across seven sites in the UK and Europe, to understand the effectiveness and viability of their technology.
Prof. Matthew J. Baker, CEO of Dxcover said: “Dxcover has patients at the heart of its thinking. This roundtable is key to changing the picture for brain tumour patients and one which we are excited to be a part of.
“We have recently launched our EMBRACE study – a pan-Europe 2,200 patient performance evaluation of the Dxcover® brain cancer liquid biopsy which will enable CE marking and provide a much-needed tool for patients.”
Dr Paul Brennan, Reader and Honorary Consultant Neurosurgeon at the University of Edinburgh said: “During several clinical studies involving patients in Scotland we have demonstrated that the Dxcover test is an efficient and effective strategy for brain tumour detection.
“The next step is to find the best route to implement this test into routine care and this roundtable brings together the stakeholders needed to achieve that.”
To find out more about The Brain Tumour Charity’s work with policymakers and healthcare professionals, visit thebraintumourcharity.org